News

BIO-CAT Partners with Kerry for Global Distribution of OPTI-BIOME MB40 Probiotic

BIO-CAT, Inc. has formed a global partnership with Kerry, the Taste & Nutrition company and their BIO-CAT Microbials, LLC probiotic products division. Effective June 2021, Kerry will lead the sales, marketing, and distribution of BIO-CAT’s proprietary probiotic strain, OPTI-BIOME MB40®.

OPTI-BIOME MB40® (Bacillus subtilis ATCC122264) is a non-GMO, highly-stable probiotic strain that the company says is an ideal ingredient for a wide array of dietary supplements and other related uses. A 2019 peer-reviewed study demonstrated promising results for the probiotic strain to support gastrointestinal health.

Kerry has extensive success marketing probiotics — the Ireland-based company has placed its GanedenBC30® (Bacillus coagulans GBI-30, 6086) probiotic in well over 1,000 food and beverage products around the world. BIO-CAT CEO Chris Schuler said he envisions similar success with MB40® in the dietary supplement space.

“Given the impressive performance of the MB40® strain and its potential to have a significant impact on the dietary supplement, functional food and beverage, and companion animal industries, we have decided to work with a partner who will help scale MB40® globally,” Schuler said. “Kerry’s expertise, commitment to develop a leading probiotic platform, access to global resources, and plans to further scientifically support MB40® make them an ideal partner.”

As part of the agreement, Kerry will apply its brand development capabilities to refresh the MB40® brand over the course of the coming months. Once fully developed, the new brand name will be supported by Kerry’s global marketing and commercial infrastructure — the company currently boasts a network of nearly 150 locations across 31 countries. According to John Quilter, VP & General Manager of Kerry’s ProActive Health business, “We are delighted to partner with Bio-Cat to further develop and market this unique and highly-stable Bacillus strain, which will complement our growing portfolio of science-backed branded ingredients in our ProActive Health portfolio.”

Recent News

07/23/2026

Activation Capital Expands the Bio+Tech Center, Doubling Laboratory Capacity to Strengthen Virginia’s Life Sciences Entrepreneurship and Innovation Ecosystem

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced an expansion of its Bio+Tech Center to support the continued growth of life sciences entrepreneurship across the region. Activation Capital’s Bio+Tech Center is a life sciences incubator located within the Virginia Bio+Technology Research Park. Serving as both a physical and programmatic

07/22/2026

Epidarex Announces Leadership Appointments

With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen our impact across the US and UK life science ecosystems, recognizing and elevating exceptional talent within our team is a vital part of that journey. These transitions reflect our continued

07/22/2026

Phlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific Officer

Phlow Corp., a U.S.-based advanced pharmaceutical contract development and manufacturing organization (CDMO), dedicated to strengthening the nation’s pharmaceutical supply chain and protecting America’s medicine cabinet, today announced the appointment of Sripathy Venkatraman, Ph.D., MBA, as Chief Scientific Officer. Venkatraman brings more than 25 years of experience in pharmaceutical development, process chemistry, manufacturing, and scientific leadership. He